M&T Bank Corp grew its holdings in shares of Alkermes PLC (NASDAQ:ALKS) by 2.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,135 shares of the company’s stock after buying an additional 200 shares during the quarter. M&T Bank Corp’s holdings in Alkermes PLC were worth $413,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Bank of New York Mellon Corp lifted its position in Alkermes PLC by 1.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,377,593 shares of the company’s stock worth $79,859,000 after buying an additional 23,506 shares in the last quarter. Atlantic Trust Group LLC lifted its position in Alkermes PLC by 4.9% during the 2nd quarter. Atlantic Trust Group LLC now owns 167,717 shares of the company’s stock worth $9,722,000 after buying an additional 7,807 shares in the last quarter. Legal & General Group Plc lifted its position in Alkermes PLC by 10.2% during the 2nd quarter. Legal & General Group Plc now owns 654,744 shares of the company’s stock worth $37,956,000 after buying an additional 60,624 shares in the last quarter. Tredje AP fonden lifted its position in Alkermes PLC by 85.5% during the 2nd quarter. Tredje AP fonden now owns 30,510 shares of the company’s stock worth $1,769,000 after buying an additional 14,060 shares in the last quarter. Finally, Teachers Advisors LLC lifted its position in Alkermes PLC by 11.8% during the 1st quarter. Teachers Advisors LLC now owns 155,311 shares of the company’s stock worth $9,086,000 after buying an additional 16,354 shares in the last quarter. 99.07% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CAO Kathryn L. Biberstein sold 13,566 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $51.29, for a total transaction of $695,800.14. Following the transaction, the chief accounting officer now directly owns 70,455 shares of the company’s stock, valued at $3,613,636.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $50.64, for a total transaction of $75,960.00. The disclosure for this sale can be found here. Insiders have sold 18,066 shares of company stock worth $930,280 over the last three months. 5.34% of the stock is owned by insiders.

Alkermes PLC (ALKS) opened at 51.50 on Monday. Alkermes PLC has a 1-year low of $41.93 and a 1-year high of $63.40. The firm’s market capitalization is $7.91 billion. The stock’s 50 day moving average is $50.99 and its 200 day moving average is $55.84.

Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The company had revenue of $218.80 million for the quarter, compared to analyst estimates of $216.54 million. During the same period last year, the firm earned ($0.01) earnings per share. The firm’s revenue was up 12.1% on a year-over-year basis. Analysts predict that Alkermes PLC will post ($0.04) EPS for the current fiscal year.

ALKS has been the topic of several analyst reports. Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Leerink Swann cut shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $68.00 to $61.00 in a research report on Tuesday, June 13th. ValuEngine raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group LLC set a $69.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, August 25th. Finally, BidaskClub cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $64.13.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/09/mt-bank-corp-has-413000-holdings-in-alkermes-plc-alks.html.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.